Quick Summary
In this meta-analysis of randomized controlled trials, supplementation with coenzyme Q10 improved one marker of endothelial function.
What was studied?
The effect of supplementation with coenzyme Q10 (CoQ10) on the following markers of endothelial function:
- Flow-mediated dilation (FMD)
- Vascular cell adhesion molecule 1 (VCAM-1)
- Intercellular adhesion molecule 1 (ICAM-1)
Who was studied?
A total of 446 men and women (average ages of 28–69), including participants with type 2 diabetes, dyslipidemia, cardiovascular disease, or polycystic ovary syndrome.
How was it studied?
A meta-analysis of 11 randomized controlled trials was performed. Three trials were conducted in Australia, 2 trials each were conducted in Iran and Italy, and 1 trial each was conducted in Iraq, China, Germany, and Singapore.
The forms of CoQ10 used were ubiquinol, ubiquinone, and ubidecarenone. The daily dose of CoQ10 ranged from 150 mg to 300 mg. The intervention duration ranged from 4 to 12 weeks.
What were the results?
Supplementation with CoQ10 increased (improved) FMD by 1.45% but had no effect on the other markers of endothelial function.
The risk of bias was low in 4 trials, unclear in 2 trials, and high in 5 trials.
This Study Summary was published on June 18, 2024.